Study summary
One dose of gene editing cut attacks by about three-quarters and left most attack-free
73%attack-free at 50 mg (weeks 1-16)
What was tested
NTLA-2002 at 25 mg or 50 mg, given once, against placebo, for hereditary angioedema.
What they found
- Attack rates were 77% lower than placebo at 50 mg.
- 73% of the 50 mg group had no attacks and needed no other treatment.
- Kallikrein levels fell 86% at 50 mg.
What it means
Set up the phase 3 HAELO trial.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.